Clinical Trial Update: GIMEMA CLL0809 Study (BendOfa) [Phase 2]

View source ↗

Summary

Phase 2 GIMEMA CLL0809 trial (BendOfa) in chronic lymphocytic leukemia; the study in relapsed or refractory CLL after up to two prior lines completed with resul…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia

Drugs mentioned

• Bendamustine (Bendamustine)
• Ofatumumab (ofatumumab)

Snippet

Sponsor: Gruppo Italiano Malattie EMatologiche dell'Adulto | Conditions: Patients With CLL Relapsing After an Initial Response (CR, PR ≥ 6 Months) Following no More Than Two Prior Treatment Lines; or, Patients With CLL Refractory (SD, PD or CR/PR < 6 Months) Following no More Than Two Prior Treatment Lines | Phase 2 | Status: COMPLETED | Results posted: 2019-01-25